Algernon Health (CSE:AGN, OTCQB:AGNPF, FRA:AGW0) on Wednesday announced “NovaScan Neuroimaging Clinics” as the new brand name for its planned US network of brain PET scanning centers, with the first location set to open in Davie, Florida.
The company said the clinics will feature the US Food and Drug Administration-cleared CareMiBrain system, a standalone PET scanner designed specifically for brain imaging and not integrated with computed tomography (CT).
The initial site, located at the HCA Florida University Medical Offices building, is expected to provide dedicated brain PET scans to support the detection and management of neurological conditions, including Alzheimer’s disease. The scans can help confirm the presence of beta-amyloid plaques associated with Alzheimer’s progression.
The facility is also expected to serve patients with other conditions such as dementia, epilepsy, Parkinson’s disease, multiple sclerosis, and brain cancer, and may be used in clinical trials for new imaging tracers.
Algernon said the CareMiBrain system delivers lower radiation exposure compared with traditional PET/CT scanners, noting that the absence of a CT component can reduce patient radiation by about 25%.
The company described the NovaScan branding as reflecting its focus on a streamlined approach to brain imaging and patient experience.
“Our goal was to settle on a name and symbol that would capture the essence of what we are planning to achieve in offering a new approach to dedicated brain PET scanning as an important component of the healthcare system,” Algernon CEO Christopher Moreau said.
He added that the clinics aim to deliver “an advanced standard of technology and service to patients and the medical community alike.”
The Davie clinic, located roughly 20 minutes southwest of Fort Lauderdale, is currently being outfitted. Algernon said it will provide an update on the official opening date and when it expects to begin accepting patient referrals.
Shares of Aftermath rose over 11% in early trading in Canada.